Mumbai pharma maker of OTC/Rx generics sold as store-brand & own-label products in US, UK, Australia/NZ, RoW.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 41 | 41 | 41 | 45 | 45 | 45 | 45 | 45 |
| Reserves | 595 | 846 | 1.2k | 1.7k | 2.0k | 2.4k | 2.6k | 3.0k |
| Borrowings | 30 | 34 | 111 | 123 | 244 | 322 | 332 | 343 |
| Other Liabilities | 236 | 307 | 323 | 322 | 372 | 451 | 422 | 494 |
| Total Liabilities | 902 | 1.2k | 1.6k | 2.2k | 2.7k | 3.2k | 3.4k | 3.9k |
| AssetsFixed Assets | 303 | 309 | 428 | 486 | 776 | 982 | 1.1k | 1.1k |
| CWIP | 0 | 12 | 3 | 10 | 9 | 27 | 7 | 15 |
| Investments | 0 | 0 | 0 | 1 | 27 | 1 | 1 | 0 |
| Other Assets | 599 | 907 | 1.2k | 1.7k | 1.9k | 2.2k | 2.4k | 2.8k |
| Total Assets | 902 | 1.2k | 1.6k | 2.2k | 2.7k | 3.2k | 3.4k | 3.9k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 27 | 233 | 179 | 99 | 237 | 230 | 207 | 458 |
| Cash from Investing | -13 | -60 | -45 | -84 | -259 | -141 | -49 | -248 |
| Cash from Financing | -21 | -114 | -15 | 80 | 198 | -69 | -65 | -71 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 14 | 174 | 133 | 53 | 184 | 22 | 35 | 329 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (21.9×) and current (28.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 16.6% growth and a 22× exit, ₹267 only delivers your return if you pay ₹194. The price is currently baking in 24% growth.
EPS grows 16.6%/yr for 5 years, then fades to 6% over 2, exits at 22×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 16.6% | 10.76 |
| FY28 | 16.6% | 12.55 |
| FY29 | 16.6% | 14.63 |
| FY30 | 16.6% | 17.06 |
| FY31 | 16.6% | 19.89 |
| FY32 | 11.3% ·fade | 22.14 |
| FY33 | 6.0% ·fade | 23.47 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.